Antitargets and drug safety:
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Weinheim
Wiley-VCH Verlag GmbH & Co KGaA
2015
|
| Schriftenreihe: | Methods and principles in medicinal chemistry
66 |
| Schlagworte: | |
| Online-Zugang: | TUM01 Volltext |
| Beschreibung: | Description based upon print version of record. - Chapter 10: Functional Cardiac Safety Evaluation of Novel Therapeutics |
| Beschreibung: | 1 Online-Ressource (XXV, 497 Seiten) |
| ISBN: | 3527673660 3527673679 9783527673667 9783527673674 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV042792550 | ||
| 003 | DE-604 | ||
| 005 | 20160112 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 150902s2015 |||| o||u| ||||||eng d | ||
| 020 | |a 3527673660 |c (ebook EPUB) |9 3-527-67366-0 | ||
| 020 | |a 3527673679 |c (ebook PDF) |9 3-527-67367-9 | ||
| 020 | |a 9783527673667 |c (ebook EPUB) |9 978-3-527-67366-7 | ||
| 020 | |a 9783527673674 |c (ebook PDF) |9 978-3-527-67367-4 | ||
| 035 | |a (OCoLC)904518353 | ||
| 035 | |a (DE-599)BVBBV042792550 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-91 | ||
| 082 | 0 | |a 615.19 |2 23 | |
| 245 | 1 | 0 | |a Antitargets and drug safety |c edited by László Urbán, Vinod F. Patel and Roy J. Vaz |
| 264 | 1 | |a Weinheim |b Wiley-VCH Verlag GmbH & Co KGaA |c 2015 | |
| 300 | |a 1 Online-Ressource (XXV, 497 Seiten) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 1 | |a Methods and principles in medicinal chemistry |v Volume 66 | |
| 500 | |a Description based upon print version of record. - Chapter 10: Functional Cardiac Safety Evaluation of Novel Therapeutics | ||
| 505 | 8 | |a Includes bibliographical references and index | |
| 505 | 8 | |a Cover; Related Titles; Title Page; Copyright; List of Contributors; Preface; A Personal Foreword; Section 1: General Concept for Target-based Safety Assessment; Chapter 1: Side Effects of Marketed Drugs: The Utility and Pitfalls of Pharmacovigilance; 1.1 Introduction; 1.2 Postmarketing Pharmacovigilance; 1.3 Polypharmacy and Pharmacological Promiscuity of Marketed Drugs; References; Chapter 2: In Silico Prediction of Drug Side Effects; 2.1 Large-Scale Prediction of Drug Activity; 2.2 Multiscale Models of Adverse Drug Reactions; References | |
| 505 | 8 | |a Chapter 3: Translational Value of Preclinical Safety Assessment: System Organ Class (SOC) Representation of Off-Targets3.1 Introduction; 3.2 Terminology: Medicinal Dictionary for Regulatory Activities (MedDRA); 3.3 Data Interpretation: Modifying Factors; 3.4 Conclusions; References; Chapter 4: Pathological Conditions Associated with the Disturbance of the 5-HT System; 4.1 Introduction; 4.2 From "St. Anthony's Fire" to Ergot Alkaloids, the Serotonin Syndrome, and Modern 5-HT Pharmacology; 4.3 Appetite-Reducing Agents, Fenfluramine, and Other 5-HT Releasers | |
| 505 | 8 | |a 4.4 Gastrointestinal and Antiemetic Indications, the 5-HT3/5-HT4 Receptor Links4.5 Antipsychotics and the 5-HT2/Dopamine D2 Link (and Many Other 5-HT Receptors); 4.6 Antimigraine Medications of Old and New and the 5-HT1B/1D Receptors; 4.7 Antidepressants/Anxiolytics Acting at 5-HT and Other Transporters; 4.8 Conclusions; References; Section 2: Hepatic Side Effects; Chapter 5: Drug-Induced Liver Injury: Clinical and Diagnostic Aspects*; 5.1 Introduction; 5.2 Special Problems of Postmarketing Hepatotoxicity; 5.3 Special Problems for New Drug Development; 5.4 Closing Considerations; References | |
| 505 | 8 | |a Chapter 6: Mechanistic Safety Biomarkers for Drug-Induced Liver Injury6.1 Introduction; 6.2 Drug-Induced Toxicity and the Liver; 6.3 Current Status of Biomarkers for the Assessment of DILI; 6.4 Novel Investigational Biomarkers for DILI; 6.5 Conclusions and Future Perspectives; References; Chapter 7: In Vitro Models for the Prediction of Drug-Induced Liver Injury in Lead Discovery; 7.1 Introduction; 7.2 Simple Systems for the Detection and Investigation of Hepatic Toxicants; 7.3 Models to Mitigate Hepatocyte Dedifferentiation; 7.4 Understanding Immune-Mediated Hepatotoxicity; 7.5 Conclusions | |
| 505 | 8 | |a ReferencesChapter 8: Transporters in the Liver; 8.1 Introduction; 8.2 Role of Organic Anion Transporters for Drug Uptake; 8.3 Drug Interaction with the Bile Salt Export Pump; 8.4 Susceptibility Factors for Drug-BSEP Interactions; 8.5 Role of BSEP in Drug Development; References; Chapter 9: Mechanistic Modeling of Drug-Induced Liver Injury (DILI); 9.1 Introduction; 9.2 Mechanistic Modules in DILIsym version 3A; 9.3 Examples of Bile Acid-Mediated Toxicity Module; 9.4 Conclusions and Future Directions; References; Section 3: Cardiovascular Side Effects | |
| 505 | 8 | |a With its focus on emerging concerns of kinase and GPCR-mediated antitarget effects, this vital reference for drug developers addresses one of the hot topics in drug safety now and in future. Divided into three major parts, the first section deals with novel technologies and includes the utility of adverse event reports to drug discovery, the translational aspects of preclinical safety findings, broader computational prediction of drug side-effects, and a description of the serotonergic system. The main part of the book looks at some of the most common antitarget-mediated side effects, focusing | |
| 650 | 4 | |a Drug development | |
| 650 | 4 | |a Drugs / Design | |
| 650 | 4 | |a Medicine | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Drug development | |
| 650 | 4 | |a Drugs |x Design | |
| 650 | 4 | |a Drugs |x Side effects | |
| 650 | 4 | |a Drug interactions | |
| 700 | 1 | |a Urban, Laszlo |d 1951- |0 (DE-588)14308058X |4 edt | |
| 700 | 1 | |a Patel, Vinod |4 edt | |
| 700 | 1 | |a Vaz, Roy J. |0 (DE-588)135534763 |4 edt | |
| 830 | 0 | |a Methods and principles in medicinal chemistry |v 66 |w (DE-604)BV044787818 |9 66 | |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=981374 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-NLEBK | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028222324 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=981374 |l TUM01 |p ZDB-4-NLEBK |q TUM_PDA_EBSCOMED_gekauft |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175027275300864 |
|---|---|
| any_adam_object | |
| author2 | Urban, Laszlo 1951- Patel, Vinod Vaz, Roy J. |
| author2_role | edt edt edt |
| author2_variant | l u lu v p vp r j v rj rjv |
| author_GND | (DE-588)14308058X (DE-588)135534763 |
| author_facet | Urban, Laszlo 1951- Patel, Vinod Vaz, Roy J. |
| building | Verbundindex |
| bvnumber | BV042792550 |
| collection | ZDB-4-NLEBK |
| contents | Includes bibliographical references and index Cover; Related Titles; Title Page; Copyright; List of Contributors; Preface; A Personal Foreword; Section 1: General Concept for Target-based Safety Assessment; Chapter 1: Side Effects of Marketed Drugs: The Utility and Pitfalls of Pharmacovigilance; 1.1 Introduction; 1.2 Postmarketing Pharmacovigilance; 1.3 Polypharmacy and Pharmacological Promiscuity of Marketed Drugs; References; Chapter 2: In Silico Prediction of Drug Side Effects; 2.1 Large-Scale Prediction of Drug Activity; 2.2 Multiscale Models of Adverse Drug Reactions; References Chapter 3: Translational Value of Preclinical Safety Assessment: System Organ Class (SOC) Representation of Off-Targets3.1 Introduction; 3.2 Terminology: Medicinal Dictionary for Regulatory Activities (MedDRA); 3.3 Data Interpretation: Modifying Factors; 3.4 Conclusions; References; Chapter 4: Pathological Conditions Associated with the Disturbance of the 5-HT System; 4.1 Introduction; 4.2 From "St. Anthony's Fire" to Ergot Alkaloids, the Serotonin Syndrome, and Modern 5-HT Pharmacology; 4.3 Appetite-Reducing Agents, Fenfluramine, and Other 5-HT Releasers 4.4 Gastrointestinal and Antiemetic Indications, the 5-HT3/5-HT4 Receptor Links4.5 Antipsychotics and the 5-HT2/Dopamine D2 Link (and Many Other 5-HT Receptors); 4.6 Antimigraine Medications of Old and New and the 5-HT1B/1D Receptors; 4.7 Antidepressants/Anxiolytics Acting at 5-HT and Other Transporters; 4.8 Conclusions; References; Section 2: Hepatic Side Effects; Chapter 5: Drug-Induced Liver Injury: Clinical and Diagnostic Aspects*; 5.1 Introduction; 5.2 Special Problems of Postmarketing Hepatotoxicity; 5.3 Special Problems for New Drug Development; 5.4 Closing Considerations; References Chapter 6: Mechanistic Safety Biomarkers for Drug-Induced Liver Injury6.1 Introduction; 6.2 Drug-Induced Toxicity and the Liver; 6.3 Current Status of Biomarkers for the Assessment of DILI; 6.4 Novel Investigational Biomarkers for DILI; 6.5 Conclusions and Future Perspectives; References; Chapter 7: In Vitro Models for the Prediction of Drug-Induced Liver Injury in Lead Discovery; 7.1 Introduction; 7.2 Simple Systems for the Detection and Investigation of Hepatic Toxicants; 7.3 Models to Mitigate Hepatocyte Dedifferentiation; 7.4 Understanding Immune-Mediated Hepatotoxicity; 7.5 Conclusions ReferencesChapter 8: Transporters in the Liver; 8.1 Introduction; 8.2 Role of Organic Anion Transporters for Drug Uptake; 8.3 Drug Interaction with the Bile Salt Export Pump; 8.4 Susceptibility Factors for Drug-BSEP Interactions; 8.5 Role of BSEP in Drug Development; References; Chapter 9: Mechanistic Modeling of Drug-Induced Liver Injury (DILI); 9.1 Introduction; 9.2 Mechanistic Modules in DILIsym version 3A; 9.3 Examples of Bile Acid-Mediated Toxicity Module; 9.4 Conclusions and Future Directions; References; Section 3: Cardiovascular Side Effects With its focus on emerging concerns of kinase and GPCR-mediated antitarget effects, this vital reference for drug developers addresses one of the hot topics in drug safety now and in future. Divided into three major parts, the first section deals with novel technologies and includes the utility of adverse event reports to drug discovery, the translational aspects of preclinical safety findings, broader computational prediction of drug side-effects, and a description of the serotonergic system. The main part of the book looks at some of the most common antitarget-mediated side effects, focusing |
| ctrlnum | (OCoLC)904518353 (DE-599)BVBBV042792550 |
| dewey-full | 615.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.19 |
| dewey-search | 615.19 |
| dewey-sort | 3615.19 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05645nmm a2200589zcb4500</leader><controlfield tag="001">BV042792550</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20160112 </controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">150902s2015 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3527673660</subfield><subfield code="c">(ebook EPUB)</subfield><subfield code="9">3-527-67366-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3527673679</subfield><subfield code="c">(ebook PDF)</subfield><subfield code="9">3-527-67367-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783527673667</subfield><subfield code="c">(ebook EPUB)</subfield><subfield code="9">978-3-527-67366-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783527673674</subfield><subfield code="c">(ebook PDF)</subfield><subfield code="9">978-3-527-67367-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)904518353</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV042792550</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-91</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.19</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antitargets and drug safety</subfield><subfield code="c">edited by László Urbán, Vinod F. Patel and Roy J. Vaz</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Weinheim</subfield><subfield code="b">Wiley-VCH Verlag GmbH & Co KGaA</subfield><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XXV, 497 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Methods and principles in medicinal chemistry</subfield><subfield code="v">Volume 66</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based upon print version of record. - Chapter 10: Functional Cardiac Safety Evaluation of Novel Therapeutics</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Cover; Related Titles; Title Page; Copyright; List of Contributors; Preface; A Personal Foreword; Section 1: General Concept for Target-based Safety Assessment; Chapter 1: Side Effects of Marketed Drugs: The Utility and Pitfalls of Pharmacovigilance; 1.1 Introduction; 1.2 Postmarketing Pharmacovigilance; 1.3 Polypharmacy and Pharmacological Promiscuity of Marketed Drugs; References; Chapter 2: In Silico Prediction of Drug Side Effects; 2.1 Large-Scale Prediction of Drug Activity; 2.2 Multiscale Models of Adverse Drug Reactions; References</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Chapter 3: Translational Value of Preclinical Safety Assessment: System Organ Class (SOC) Representation of Off-Targets3.1 Introduction; 3.2 Terminology: Medicinal Dictionary for Regulatory Activities (MedDRA); 3.3 Data Interpretation: Modifying Factors; 3.4 Conclusions; References; Chapter 4: Pathological Conditions Associated with the Disturbance of the 5-HT System; 4.1 Introduction; 4.2 From "St. Anthony's Fire" to Ergot Alkaloids, the Serotonin Syndrome, and Modern 5-HT Pharmacology; 4.3 Appetite-Reducing Agents, Fenfluramine, and Other 5-HT Releasers</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">4.4 Gastrointestinal and Antiemetic Indications, the 5-HT3/5-HT4 Receptor Links4.5 Antipsychotics and the 5-HT2/Dopamine D2 Link (and Many Other 5-HT Receptors); 4.6 Antimigraine Medications of Old and New and the 5-HT1B/1D Receptors; 4.7 Antidepressants/Anxiolytics Acting at 5-HT and Other Transporters; 4.8 Conclusions; References; Section 2: Hepatic Side Effects; Chapter 5: Drug-Induced Liver Injury: Clinical and Diagnostic Aspects*; 5.1 Introduction; 5.2 Special Problems of Postmarketing Hepatotoxicity; 5.3 Special Problems for New Drug Development; 5.4 Closing Considerations; References</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Chapter 6: Mechanistic Safety Biomarkers for Drug-Induced Liver Injury6.1 Introduction; 6.2 Drug-Induced Toxicity and the Liver; 6.3 Current Status of Biomarkers for the Assessment of DILI; 6.4 Novel Investigational Biomarkers for DILI; 6.5 Conclusions and Future Perspectives; References; Chapter 7: In Vitro Models for the Prediction of Drug-Induced Liver Injury in Lead Discovery; 7.1 Introduction; 7.2 Simple Systems for the Detection and Investigation of Hepatic Toxicants; 7.3 Models to Mitigate Hepatocyte Dedifferentiation; 7.4 Understanding Immune-Mediated Hepatotoxicity; 7.5 Conclusions</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">ReferencesChapter 8: Transporters in the Liver; 8.1 Introduction; 8.2 Role of Organic Anion Transporters for Drug Uptake; 8.3 Drug Interaction with the Bile Salt Export Pump; 8.4 Susceptibility Factors for Drug-BSEP Interactions; 8.5 Role of BSEP in Drug Development; References; Chapter 9: Mechanistic Modeling of Drug-Induced Liver Injury (DILI); 9.1 Introduction; 9.2 Mechanistic Modules in DILIsym version 3A; 9.3 Examples of Bile Acid-Mediated Toxicity Module; 9.4 Conclusions and Future Directions; References; Section 3: Cardiovascular Side Effects</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">With its focus on emerging concerns of kinase and GPCR-mediated antitarget effects, this vital reference for drug developers addresses one of the hot topics in drug safety now and in future. Divided into three major parts, the first section deals with novel technologies and includes the utility of adverse event reports to drug discovery, the translational aspects of preclinical safety findings, broader computational prediction of drug side-effects, and a description of the serotonergic system. The main part of the book looks at some of the most common antitarget-mediated side effects, focusing</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs / Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Side effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug interactions</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Urban, Laszlo</subfield><subfield code="d">1951-</subfield><subfield code="0">(DE-588)14308058X</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Patel, Vinod</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vaz, Roy J.</subfield><subfield code="0">(DE-588)135534763</subfield><subfield code="4">edt</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Methods and principles in medicinal chemistry</subfield><subfield code="v">66</subfield><subfield code="w">(DE-604)BV044787818</subfield><subfield code="9">66</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=981374</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-NLEBK</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028222324</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=981374</subfield><subfield code="l">TUM01</subfield><subfield code="p">ZDB-4-NLEBK</subfield><subfield code="q">TUM_PDA_EBSCOMED_gekauft</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV042792550 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:09:45Z |
| institution | BVB |
| isbn | 3527673660 3527673679 9783527673667 9783527673674 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028222324 |
| oclc_num | 904518353 |
| open_access_boolean | |
| owner | DE-91 DE-BY-TUM |
| owner_facet | DE-91 DE-BY-TUM |
| physical | 1 Online-Ressource (XXV, 497 Seiten) |
| psigel | ZDB-4-NLEBK ZDB-4-NLEBK TUM_PDA_EBSCOMED_gekauft |
| publishDate | 2015 |
| publishDateSearch | 2015 |
| publishDateSort | 2015 |
| publisher | Wiley-VCH Verlag GmbH & Co KGaA |
| record_format | marc |
| series | Methods and principles in medicinal chemistry |
| series2 | Methods and principles in medicinal chemistry |
| spelling | Antitargets and drug safety edited by László Urbán, Vinod F. Patel and Roy J. Vaz Weinheim Wiley-VCH Verlag GmbH & Co KGaA 2015 1 Online-Ressource (XXV, 497 Seiten) txt rdacontent c rdamedia cr rdacarrier Methods and principles in medicinal chemistry Volume 66 Description based upon print version of record. - Chapter 10: Functional Cardiac Safety Evaluation of Novel Therapeutics Includes bibliographical references and index Cover; Related Titles; Title Page; Copyright; List of Contributors; Preface; A Personal Foreword; Section 1: General Concept for Target-based Safety Assessment; Chapter 1: Side Effects of Marketed Drugs: The Utility and Pitfalls of Pharmacovigilance; 1.1 Introduction; 1.2 Postmarketing Pharmacovigilance; 1.3 Polypharmacy and Pharmacological Promiscuity of Marketed Drugs; References; Chapter 2: In Silico Prediction of Drug Side Effects; 2.1 Large-Scale Prediction of Drug Activity; 2.2 Multiscale Models of Adverse Drug Reactions; References Chapter 3: Translational Value of Preclinical Safety Assessment: System Organ Class (SOC) Representation of Off-Targets3.1 Introduction; 3.2 Terminology: Medicinal Dictionary for Regulatory Activities (MedDRA); 3.3 Data Interpretation: Modifying Factors; 3.4 Conclusions; References; Chapter 4: Pathological Conditions Associated with the Disturbance of the 5-HT System; 4.1 Introduction; 4.2 From "St. Anthony's Fire" to Ergot Alkaloids, the Serotonin Syndrome, and Modern 5-HT Pharmacology; 4.3 Appetite-Reducing Agents, Fenfluramine, and Other 5-HT Releasers 4.4 Gastrointestinal and Antiemetic Indications, the 5-HT3/5-HT4 Receptor Links4.5 Antipsychotics and the 5-HT2/Dopamine D2 Link (and Many Other 5-HT Receptors); 4.6 Antimigraine Medications of Old and New and the 5-HT1B/1D Receptors; 4.7 Antidepressants/Anxiolytics Acting at 5-HT and Other Transporters; 4.8 Conclusions; References; Section 2: Hepatic Side Effects; Chapter 5: Drug-Induced Liver Injury: Clinical and Diagnostic Aspects*; 5.1 Introduction; 5.2 Special Problems of Postmarketing Hepatotoxicity; 5.3 Special Problems for New Drug Development; 5.4 Closing Considerations; References Chapter 6: Mechanistic Safety Biomarkers for Drug-Induced Liver Injury6.1 Introduction; 6.2 Drug-Induced Toxicity and the Liver; 6.3 Current Status of Biomarkers for the Assessment of DILI; 6.4 Novel Investigational Biomarkers for DILI; 6.5 Conclusions and Future Perspectives; References; Chapter 7: In Vitro Models for the Prediction of Drug-Induced Liver Injury in Lead Discovery; 7.1 Introduction; 7.2 Simple Systems for the Detection and Investigation of Hepatic Toxicants; 7.3 Models to Mitigate Hepatocyte Dedifferentiation; 7.4 Understanding Immune-Mediated Hepatotoxicity; 7.5 Conclusions ReferencesChapter 8: Transporters in the Liver; 8.1 Introduction; 8.2 Role of Organic Anion Transporters for Drug Uptake; 8.3 Drug Interaction with the Bile Salt Export Pump; 8.4 Susceptibility Factors for Drug-BSEP Interactions; 8.5 Role of BSEP in Drug Development; References; Chapter 9: Mechanistic Modeling of Drug-Induced Liver Injury (DILI); 9.1 Introduction; 9.2 Mechanistic Modules in DILIsym version 3A; 9.3 Examples of Bile Acid-Mediated Toxicity Module; 9.4 Conclusions and Future Directions; References; Section 3: Cardiovascular Side Effects With its focus on emerging concerns of kinase and GPCR-mediated antitarget effects, this vital reference for drug developers addresses one of the hot topics in drug safety now and in future. Divided into three major parts, the first section deals with novel technologies and includes the utility of adverse event reports to drug discovery, the translational aspects of preclinical safety findings, broader computational prediction of drug side-effects, and a description of the serotonergic system. The main part of the book looks at some of the most common antitarget-mediated side effects, focusing Drug development Drugs / Design Medicine MEDICAL / Pharmacology bisacsh Medizin Drugs Design Drugs Side effects Drug interactions Urban, Laszlo 1951- (DE-588)14308058X edt Patel, Vinod edt Vaz, Roy J. (DE-588)135534763 edt Methods and principles in medicinal chemistry 66 (DE-604)BV044787818 66 http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=981374 Aggregator Volltext |
| spellingShingle | Antitargets and drug safety Methods and principles in medicinal chemistry Includes bibliographical references and index Cover; Related Titles; Title Page; Copyright; List of Contributors; Preface; A Personal Foreword; Section 1: General Concept for Target-based Safety Assessment; Chapter 1: Side Effects of Marketed Drugs: The Utility and Pitfalls of Pharmacovigilance; 1.1 Introduction; 1.2 Postmarketing Pharmacovigilance; 1.3 Polypharmacy and Pharmacological Promiscuity of Marketed Drugs; References; Chapter 2: In Silico Prediction of Drug Side Effects; 2.1 Large-Scale Prediction of Drug Activity; 2.2 Multiscale Models of Adverse Drug Reactions; References Chapter 3: Translational Value of Preclinical Safety Assessment: System Organ Class (SOC) Representation of Off-Targets3.1 Introduction; 3.2 Terminology: Medicinal Dictionary for Regulatory Activities (MedDRA); 3.3 Data Interpretation: Modifying Factors; 3.4 Conclusions; References; Chapter 4: Pathological Conditions Associated with the Disturbance of the 5-HT System; 4.1 Introduction; 4.2 From "St. Anthony's Fire" to Ergot Alkaloids, the Serotonin Syndrome, and Modern 5-HT Pharmacology; 4.3 Appetite-Reducing Agents, Fenfluramine, and Other 5-HT Releasers 4.4 Gastrointestinal and Antiemetic Indications, the 5-HT3/5-HT4 Receptor Links4.5 Antipsychotics and the 5-HT2/Dopamine D2 Link (and Many Other 5-HT Receptors); 4.6 Antimigraine Medications of Old and New and the 5-HT1B/1D Receptors; 4.7 Antidepressants/Anxiolytics Acting at 5-HT and Other Transporters; 4.8 Conclusions; References; Section 2: Hepatic Side Effects; Chapter 5: Drug-Induced Liver Injury: Clinical and Diagnostic Aspects*; 5.1 Introduction; 5.2 Special Problems of Postmarketing Hepatotoxicity; 5.3 Special Problems for New Drug Development; 5.4 Closing Considerations; References Chapter 6: Mechanistic Safety Biomarkers for Drug-Induced Liver Injury6.1 Introduction; 6.2 Drug-Induced Toxicity and the Liver; 6.3 Current Status of Biomarkers for the Assessment of DILI; 6.4 Novel Investigational Biomarkers for DILI; 6.5 Conclusions and Future Perspectives; References; Chapter 7: In Vitro Models for the Prediction of Drug-Induced Liver Injury in Lead Discovery; 7.1 Introduction; 7.2 Simple Systems for the Detection and Investigation of Hepatic Toxicants; 7.3 Models to Mitigate Hepatocyte Dedifferentiation; 7.4 Understanding Immune-Mediated Hepatotoxicity; 7.5 Conclusions ReferencesChapter 8: Transporters in the Liver; 8.1 Introduction; 8.2 Role of Organic Anion Transporters for Drug Uptake; 8.3 Drug Interaction with the Bile Salt Export Pump; 8.4 Susceptibility Factors for Drug-BSEP Interactions; 8.5 Role of BSEP in Drug Development; References; Chapter 9: Mechanistic Modeling of Drug-Induced Liver Injury (DILI); 9.1 Introduction; 9.2 Mechanistic Modules in DILIsym version 3A; 9.3 Examples of Bile Acid-Mediated Toxicity Module; 9.4 Conclusions and Future Directions; References; Section 3: Cardiovascular Side Effects With its focus on emerging concerns of kinase and GPCR-mediated antitarget effects, this vital reference for drug developers addresses one of the hot topics in drug safety now and in future. Divided into three major parts, the first section deals with novel technologies and includes the utility of adverse event reports to drug discovery, the translational aspects of preclinical safety findings, broader computational prediction of drug side-effects, and a description of the serotonergic system. The main part of the book looks at some of the most common antitarget-mediated side effects, focusing Drug development Drugs / Design Medicine MEDICAL / Pharmacology bisacsh Medizin Drugs Design Drugs Side effects Drug interactions |
| title | Antitargets and drug safety |
| title_auth | Antitargets and drug safety |
| title_exact_search | Antitargets and drug safety |
| title_full | Antitargets and drug safety edited by László Urbán, Vinod F. Patel and Roy J. Vaz |
| title_fullStr | Antitargets and drug safety edited by László Urbán, Vinod F. Patel and Roy J. Vaz |
| title_full_unstemmed | Antitargets and drug safety edited by László Urbán, Vinod F. Patel and Roy J. Vaz |
| title_short | Antitargets and drug safety |
| title_sort | antitargets and drug safety |
| topic | Drug development Drugs / Design Medicine MEDICAL / Pharmacology bisacsh Medizin Drugs Design Drugs Side effects Drug interactions |
| topic_facet | Drug development Drugs / Design Medicine MEDICAL / Pharmacology Medizin Drugs Design Drugs Side effects Drug interactions |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=981374 |
| volume_link | (DE-604)BV044787818 |
| work_keys_str_mv | AT urbanlaszlo antitargetsanddrugsafety AT patelvinod antitargetsanddrugsafety AT vazroyj antitargetsanddrugsafety |